114 related articles for article (PubMed ID: 35500202)
1. Discovery of Natural Ursane-type SENP1 Inhibitors and the Platinum Resistance Reversal Activity Against Human Ovarian Cancer Cells: A Structure-Activity Relationship Study.
Wei H; Guo J; Sun X; Gou W; Ning H; Shang H; Liu Q; Hou W; Li Y
J Nat Prod; 2022 May; 85(5):1248-1255. PubMed ID: 35500202
[TBL] [Abstract][Full Text] [Related]
2. SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance.
Li J; Wu R; Yung MMH; Sun J; Li Z; Yang H; Zhang Y; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Zheng W; Wei H; Gao Y; Nemes P; Pei H; Chan DW; Li Y; Zhu W
Cell Death Dis; 2021 Apr; 12(4):341. PubMed ID: 33795649
[TBL] [Abstract][Full Text] [Related]
3. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Shi L; Yu H; Zhang W; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
[TBL] [Abstract][Full Text] [Related]
4. Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer.
Zhang Y; Wei H; Zhou Y; Li Z; Gou W; Meng Y; Zheng W; Li J; Li Y; Zhu W
Clin Transl Med; 2021 Dec; 11(12):e649. PubMed ID: 34954894
[No Abstract] [Full Text] [Related]
5. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
6. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.
Ao Q; Su W; Guo S; Cai L; Huang L
Sci Rep; 2015 Nov; 5():16396. PubMed ID: 26548925
[TBL] [Abstract][Full Text] [Related]
7. Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers.
Wei J; Wang H; Zheng Q; Zhang J; Chen Z; Wang J; Ouyang L; Wang Y
Eur J Med Chem; 2022 Nov; 241():114650. PubMed ID: 35939992
[TBL] [Abstract][Full Text] [Related]
8. Discovery and radiosensitization research of ursolic acid derivatives as SENP1 inhibitors.
Wei H; Guo J; Sun X; Gou W; Ning H; Fang Z; Liu Q; Hou W; Li Y
Eur J Med Chem; 2022 Jan; 227():113918. PubMed ID: 34688014
[TBL] [Abstract][Full Text] [Related]
9. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Li Z; Wang Q; Zhang W; Yang Z; Li L
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
[TBL] [Abstract][Full Text] [Related]
10. Identification of SENP1 inhibitors through in silico screening and rational drug design.
Zhao Y; Wang Z; Zhang J; Zhou H
Eur J Med Chem; 2016 Oct; 122():178-184. PubMed ID: 27344494
[TBL] [Abstract][Full Text] [Related]
11. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
12. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
[TBL] [Abstract][Full Text] [Related]
13. Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin‑resistant SKOV3/DDP ovarian cancer cells.
Zhong Y; Le F; Cheng J; Luo C; Zhang X; Wu X; Xu F; Zuo Q; Tan B
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760192
[TBL] [Abstract][Full Text] [Related]
14. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.
Jazaeri AA; Shibata E; Park J; Bryant JL; Conaway MR; Modesitt SC; Smith PG; Milhollen MA; Berger AJ; Dutta A
Mol Cancer Ther; 2013 Oct; 12(10):1958-67. PubMed ID: 23939375
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Kunos C; Radivoyevitch T; Abdul-Karim FW; Fanning J; Abulafia O; Bonebrake AJ; Usha L
J Transl Med; 2012 Apr; 10():79. PubMed ID: 22541066
[TBL] [Abstract][Full Text] [Related]
16. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
[TBL] [Abstract][Full Text] [Related]
17. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
18. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F
Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260
[TBL] [Abstract][Full Text] [Related]
19. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]